Cardinal Health Reports Strong Q2 FY26 Results, Completes $2.4B Solaris Acquisition, and Announces Significant Share Repurchases
Summary
Cardinal Health reported robust second-quarter fiscal year 2026 financial results, driven by strong revenue and earnings growth, and detailed the completion of its $2.4 billion Solaris Health acquisition and substantial share repurchase activity.
Key Events
-
Strong Q2 FY26 Financial Performance
Reported 19% GAAP diluted EPS growth and 36% non-GAAP diluted EPS growth for the quarter, alongside 19% revenue growth, driven by pharmaceutical and specialty sales.
-
Solaris Health Acquisition Completed
Finalized the acquisition of Solaris Health, a urology MSO, for approximately $1.9 billion in cash and $500 million in equity, significantly expanding its MSO platform.
-
Substantial Share Repurchases
Deployed $750 million for common share repurchases during the six months ended December 31, 2025, with $2.0 billion remaining under the current program.
-
New IRS Tax Contingency
Disclosed a Notice of Proposed Adjustment from the IRS asserting an additional $160 million federal income tax liability plus interest related to a 2017 acquisition.
Analysis
The company demonstrated strong operational performance in Q2 FY26, with significant increases in both GAAP and non-GAAP revenue and EPS, largely fueled by branded and specialty pharmaceutical sales and contributions from recent acquisitions. The completion of the $2.4 billion Solaris Health acquisition further expands its multi-specialty MSO platform, a key strategic growth area. Additionally, the company deployed $750 million in share repurchases, signaling confidence and returning value to shareholders. While the filing also disclosed a new $160 million IRS tax contingency, the overall financial strength and strategic execution presented in this comprehensive quarterly report are likely to be viewed positively by investors.
At the time of this filing, CAH was trading at $212.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $49.1B. The 52-week trading range was $120.72 to $220.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.